Navigation Links
Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results
Date:5/9/2011

MISSISSAUGA, Ontario, May 9, 2011 /PRNewswire/ --

  • 2011 First Quarter Total Revenue $565 million, including $36 million related to out-license of Cloderm
  • Pro forma organic growth for the combined company, excluding the impact of foreign exchange and acquisitions, was approximately 7%
  • Excluding impact from Diastat and Efudex, pro forma organic growth for the combined company was approximately 11%
  • 2011 First Quarter GAAP EPS $0.02; Cash EPS $0.62
  • Excluding impact from Cloderm out-licensing, Cash EPS was $0.56
  • 2011 First Quarter GAAP Cash Flow from Operations was $86 million; Adjusted Cash Flow from Operations was $204 million  
  • 2011 Guidance increased to $2.65 - $2.90 Cash EPS

  • Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces first quarter financial results for 2011.

    "Our performance in the first quarter is a strong start to what I believe will be another successful year for Valeant," said J. Michael Pearson, chairman and chief executive officer.  "Our specialty businesses performed well and our branded generic operations, in particular Central Europe, exceeded our expectations this quarter.  This strong performance is a testament to our diversified business model that gives us the ability to pursue acquisition opportunities, while continuing to deliver strong operating results."

    RevenueTotal revenue was $565.0 million in the first quarter of 2011 as compared to $219.6 million in the first quarter of 2010.  Included in total revenue was $36.0 million of alliance and royalty revenue related to the out-license of product rights for Cloderm, a mid-potency steroid with an annual revenue run rate of approximately $7 million, that was completed on March 31, 2011.  Product sales were $500.4 million in the fi
    '/>"/>

    SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Valeant to Acquire Polish Products
    2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
    3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
    4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
    5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
    6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
    7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
    8. Valeant Announces Pricing of Senior Notes
    9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
    10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
    11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/3/2015)... 2015 Report Details Ovarian ... Industry Changes and Emerging Opportunities What,s the future ... new study forecasts those pharmaceutical revenues. There you ... You also explore trends, results, treatments, R&D, and ... revenue predictions to 2025 at overall world market, ...
    (Date:9/3/2015)... Sept. 3,  2015 About Vision Care ... products considered for this report are Rx lenses, ... products are primarily used by consumer for vision ... Rx lenses and contact lenses require a prescription ... are cosmetic products that can be purchased like ...
    (Date:9/3/2015)... 3, 2015 This Defibrillators are critical life ... of lives across globe. This report provides in-depth analysis ... Saudi Arabia . Stakeholders for this report include ... and regulatory bodies. The Saudi Arabia ... by products and by end users. In terms of ...
    Breaking Medicine Technology:Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6Vision Care Market in the US 2015-2019 2Saudi Arabia Defibrillators Market: & Advanced Life Support Defibrillators; End Users; Industry Analysis, Size, Volume, Growth, Trends and Forecast 2014 - 2020 2
    ... SAN FRANCISCO, May 15, 2012  Nile Therapeutics, Inc. (OTCQB: ... heart failure patients, today announced its first quarter financial ... quarter of 2012, Nile reported a net operating loss ... outstanding for the quarter were 39.7 million. Nile reported ...
    ... a provider of products and services for people with ... Michael Johnson, formula racing,s first paralyzed driver. ... Tires USF2000 Championship Powered by Mazda, the first step ... for drivers seeking a professional racing career. Johnson,s goal ...
    Cached Medicine Technology:Nile Therapeutics Reports 2012 First Quarter Financial Results 2Nile Therapeutics Reports 2012 First Quarter Financial Results 3First Paralyzed Formula Race Car Driver's "Road to Indy" Sponsored By Coloplast 2
    (Date:9/3/2015)... ... September 03, 2015 , ... NanoCytomics LLC ... medical technology company that will bring low-cost cancer pre-screening tests to primary care ... proprietary and automated technology platform detects and measures cellular changes at the nanoscale ...
    (Date:9/3/2015)... ... September 03, 2015 , ... ... partner for the Academy of Integrative Health & Medicine (AIHM) Interprofessional Fellowship in ... of Tieraona Low Dog, MD, an internationally renowned educator, physician and thought leader ...
    (Date:9/3/2015)... ... September 03, 2015 , ... The ... Experience Conference 2016, to be held April 13-15 at Sheraton Hotel in Dallas, ... bringing together the collective voices of healthcare leaders, staff, physicians, patients and families ...
    (Date:9/3/2015)... ... September 03, 2015 , ... Topical BioMedics, Inc., ... destination of his six-month, 10,000 mile journey from Santiago, Chile to Times Square ... calls the “Connecting Las Americas” project—Max crossed six countries in 168 days on ...
    (Date:9/3/2015)... ... September 03, 2015 , ... BedJet released a new version ... for pre-order on Kickstarter. Today the BedJet v2 pre-order campaign blazed past ... 0.1% most successful campaigns ever on crowdfunding giant Kickstarter. , Simple to use and ...
    Breaking Medicine News(10 mins):Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 3Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 3Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 2Health News:Patient Experience Conference 2016 Program Announced by The Beryl Institute 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 4Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 5Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 6Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 3
    ... Switzerland) -- The International AIDS Society (IAS) and the ... the recipients of their third annual joint research fellowships. ... to advance scientific understanding of the linkages between drug ... Young researchers from China and Indonesia will be awarded ...
    ... most important determinants of an individual,s risk of cancer ... whether and at what ages close relatives were ... screening examinations such as colonoscopies and mammograms. In ... Association a multi-institutional research team reports that changes ...
    ... , TUESDAY, July 12 (HealthDay News) -- People,s employment ... during the workweek, but men and women are affected differently, ... Institute on Aging measured the levels of physical activity in ... Survey, which gathers data on about 5,000 people each year. ...
    ... -- Scorching heat and oppressive humidity continued to grip much ... -- and in some cases 100 degrees -- from the ... doctors to warn that high temperatures can cause serious -- ... has ways of keeping itself cool, by letting heat escape ...
    ... in adults is not related to how they rate ... In a study of self-rated health (SRH) published this ... Lysack, Ph.D., deputy director of WSU,s Institute of Gerontology, ... and Stewart Neufeld, Ph.D., assistant professor in the Institute ...
    ... a boost were originally developed as temporary measures for ... has improved, these ventricular assist devices commonly operate in ... whose implant this month celebrates its one-year anniversary. , ... cord that protrudes through the patient,s belly is cumbersome ...
    Cached Medicine News:Health News:Fellowships for outstanding research in drug use and HIV awarded by IAS and NIDA 2Health News:Changes in family history of cancer can impact screening recommendations 2Health News:Changes in family history of cancer can impact screening recommendations 3Health News:Physical Activity Levels Linked to Employment Status 2Health News:Soaring Temps Can Pose Serious Health Risks 2Health News:Soaring Temps Can Pose Serious Health Risks 3Health News:Severity of spinal cord injury has no impact on how adults rate their health, WSU research finds 2Health News:Wireless power could cut cord for patients with implanted heart pumps 2Health News:Wireless power could cut cord for patients with implanted heart pumps 3
    Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 110o. Most popular size or model....
    Double ended with 0.5 mm x 10 mm and 0.5 mm x 15 mm blades. Both blades gently curved. Square serrated handle with polished finish. Most popular size or model....
    11 mm angled tip with gently curved blade. Flat serrated handle with polished finish....
    Angled tip with gently curved blade. Short hexagonal handle with polished finish. 0.5 mm x 15 mm tip....
    Medicine Products: